Löffler K U
Universitäts-Augenklinik Bonn, Ernst-Abbe-Strasse 2, 53127 Bonn.
Ophthalmologe. 2006 Dec;103(12):1057-63; quiz 1064. doi: 10.1007/s00347-006-1431-7.
Neovascular glaucoma, as a typical secondary glaucoma, is due to ocular or (earlier) systemic diseases. The formation of a fibrovascular membrane on the anterior surface of the iris (rubeosis iridis) and extending into the chamber angle leads to irreversible obliteration of the outflow system, with a corresponding rise in intraocular pressure. The most frequent cause is retinal ischaemia resulting either from vascular occlusion or from diabetic alterations. The differential diagnosis must include acute angle-closure glaucoma and uncontrolled open-angle glaucoma. Treatment is aimed at eliminating the actual cause or at least reducing the risk factors (e.g. by retinal laser coagulation), or consists in cyclodestructive procedures. Medicamentous therapy comprises anti-inflammatory agents (steroids, cycloplegic agents) and substances that reduce the production of aqueous humour (carbonic anhydrase antagonists, beta blockers). In the near future, antiangiogenic medication might be another effective option. For end-stage neovascular glaucoma, the implantation of drainage devices is also discussed.
新生血管性青光眼作为一种典型的继发性青光眼,是由眼部或(早期)全身性疾病引起的。虹膜前表面纤维血管膜(虹膜红变)的形成并延伸至房角会导致流出系统不可逆地闭塞,从而使眼压相应升高。最常见的病因是血管阻塞或糖尿病性病变导致的视网膜缺血。鉴别诊断必须包括急性闭角型青光眼和未控制的开角型青光眼。治疗旨在消除实际病因或至少降低危险因素(如通过视网膜激光光凝),或采用睫状体破坏手术。药物治疗包括抗炎药(类固醇、睫状肌麻痹剂)和减少房水生成的物质(碳酸酐酶拮抗剂、β受体阻滞剂)。在不久的将来,抗血管生成药物可能是另一种有效的选择。对于晚期新生血管性青光眼,也会讨论引流装置的植入。